Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Hepatectomy or/with Metastatectomy for Recurrent Intrahepatic Cholangiocarcinoma: Of Promise for Selected Patients

View through CrossRef
Introduction: Intrahepatic cholangiocarcinoma (ICC) has devastating outcomes owing to its advanced stage at diagnosis and high recurrence after hepatectomy. There is no preferred treatment for recurrent ICC. We retrospectively reviewed our patients who underwent repeated operations for recurrent ICCs based on their different indications to appraise the outcomes. Methods: In all, 160 out of 216 patients with ICC (71.4%) experienced recurrence after curative resection from 1977 to 2014. The patterns of recurrence were categorized according to the locations and numbers of recurrent tumors. Results: Patients with merely intrahepatic recurrence (n = 38) had superior overall survival (OS) compared with those with beyond intrahepatic recurrence (p < 0.0001). Twenty-seven out of 160 patients (16.8%) underwent repeat hepatectomy or/with metastatectomy for recurrence and had superior OS when compared to the remaining 133 patients who received nonoperative treatment/palliation (85.6 months versus 20.9 months, p < 0.001). Furthermore, patients suitable for repeat hepatectomy in the intrahepatic recurrent group (n = 12) had superior post-recurrence overall survival (PROS) than the remaining 26 patients receiving nonoperative treatment (61.6 months versus 14.7 months, p < 0.05). Conclusion: Liver is the most commonly involved site of recurrent ICC. However, merely intrahepatic recurrence may have a favorable prognosis compared to recurrence involving other sites. Aggressive hepatectomy may provide a survival benefit in selected patients.
Title: Hepatectomy or/with Metastatectomy for Recurrent Intrahepatic Cholangiocarcinoma: Of Promise for Selected Patients
Description:
Introduction: Intrahepatic cholangiocarcinoma (ICC) has devastating outcomes owing to its advanced stage at diagnosis and high recurrence after hepatectomy.
There is no preferred treatment for recurrent ICC.
We retrospectively reviewed our patients who underwent repeated operations for recurrent ICCs based on their different indications to appraise the outcomes.
Methods: In all, 160 out of 216 patients with ICC (71.
4%) experienced recurrence after curative resection from 1977 to 2014.
The patterns of recurrence were categorized according to the locations and numbers of recurrent tumors.
Results: Patients with merely intrahepatic recurrence (n = 38) had superior overall survival (OS) compared with those with beyond intrahepatic recurrence (p < 0.
0001).
Twenty-seven out of 160 patients (16.
8%) underwent repeat hepatectomy or/with metastatectomy for recurrence and had superior OS when compared to the remaining 133 patients who received nonoperative treatment/palliation (85.
6 months versus 20.
9 months, p < 0.
001).
Furthermore, patients suitable for repeat hepatectomy in the intrahepatic recurrent group (n = 12) had superior post-recurrence overall survival (PROS) than the remaining 26 patients receiving nonoperative treatment (61.
6 months versus 14.
7 months, p < 0.
05).
Conclusion: Liver is the most commonly involved site of recurrent ICC.
However, merely intrahepatic recurrence may have a favorable prognosis compared to recurrence involving other sites.
Aggressive hepatectomy may provide a survival benefit in selected patients.

Related Results

c‐erbB‐2 and c‐Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma
c‐erbB‐2 and c‐Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma
c‐erbB‐2 and c‐Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma Aims: The c‐erbB‐2 and c‐Met proto‐oncogenes are important for ...
Regional versus Extended Lymph Node Dissection for Intrahepatic Cholangiocarcinoma: a randomized controlled trial protocol
Regional versus Extended Lymph Node Dissection for Intrahepatic Cholangiocarcinoma: a randomized controlled trial protocol
ABSTRACTIntroductionThe mainstay treatment for intrahepatic cholangiocarcinoma is surgical resection, the impact of lymph node dissection and the scope of lymph node dissection for...
Caudate lobe-based minimally invasive anatomic hepatectomy: a retrospective study
Caudate lobe-based minimally invasive anatomic hepatectomy: a retrospective study
Abstract Background: Anatomic hepatectomy has become a crucial surgical procedure in the liver section. The function and role of the caudate lobe in anatomic hepatectomy re...
Clinicopathological Factors Predicting Long‐term Overall Survival after Hepatectomy for Peripheral Cholangiocarcinoma
Clinicopathological Factors Predicting Long‐term Overall Survival after Hepatectomy for Peripheral Cholangiocarcinoma
AbstractPeripheral cholangiocarcinoma (PCC) is clinically challenging because patients typically do not present until the disease is relatively advanced. Three‐year to 5‐year survi...
The diagnosis and treatment of cholangiocarcinoma
The diagnosis and treatment of cholangiocarcinoma
Background: Cholangiocarcinoma (CCA) is the second most common primary hepatic tumor. In recent years, its prognosis has improved because of wide resections and the establishment o...
Risk Factors of Post-Partial Hepatectomy Acute Myocardial Infarction : A Retrospective Nationwide Inpatient Sample Database Study
Risk Factors of Post-Partial Hepatectomy Acute Myocardial Infarction : A Retrospective Nationwide Inpatient Sample Database Study
Abstract Background The aftermath of partial hepatectomy often results in a severe condition known as acute myocardial infarction (AMI), which may lead to death and frequen...
Multimodal treatment of an advanced intrahepatic cholangiocarcinoma and its recurrence – a case report
Multimodal treatment of an advanced intrahepatic cholangiocarcinoma and its recurrence – a case report
Introduction: Intrahepatic cholangiocarcinoma (ICC) is rare and often diagnosed in an advanced stage. Neoadjuvant therapy is not established and data on its value are in palliative...

Back to Top